PMID- 31784745
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20211204
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 221
IP  - 9
DP  - 2020 Apr 7
TI  - Total and Unbound Bictegravir Concentrations and Viral Suppression in 
      Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish 
      HIV/AIDS Research Network, PreEC/RIS 56).
PG  - 1425-1428
LID - 10.1093/infdis/jiz624 [doi]
AB  - We determined total and unbound concentrations of bictegravir (BIC) in 
      cerebrospinal fluid (CSF) in 15 asymptomatic, virologically suppressed patients. 
      The median plasma and CSF total BIC concentrations were 1837.1 ng/mL 
      (interquartile range [IQR], 1237.2-2586.7) and 6.9 (IQR, 4.8-10.9), respectively. 
      Median unbound BIC concentration was 2.48 ng/mL (IQR, 1.6-3.7). Total and unbound 
      BIC CSF concentrations were above the half-maximal effective concentration value 
      in all patients, and all subjects had human immunodeficiency virus viral 
      suppression in plasma and CSF. Bictegravir may contribute to inhibit viral 
      replication in this compartment.
CI  - (c) The Author(s) 2019. Published by Oxford University Press for the Infectious 
      Diseases Society of America. All rights reserved. For permissions, e-mail: 
      journals.permissions@oup.com.
FAU - Tiraboschi, Juan
AU  - Tiraboschi J
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
FAU - Imaz, Arkaitz
AU  - Imaz A
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
FAU - Khoo, Saye
AU  - Khoo S
AD  - Microbiology Service, Hospital Universitari de Bellvitge, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
AD  - University of Liverpool, Liverpool, United Kingdom.
FAU - Niubo, Jordi
AU  - Niubo J
AD  - Microbiology Service, Hospital Universitari de Bellvitge, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Prieto, Paula
AU  - Prieto P
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
FAU - Saumoy, Maria
AU  - Saumoy M
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
FAU - Penchala, Sujan Dilly
AU  - Penchala SD
AD  - Microbiology Service, Hospital Universitari de Bellvitge, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Garcia, Benito
AU  - Garcia B
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
FAU - Padilla, Cristina
AU  - Padilla C
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
FAU - Videla, Sebastian
AU  - Videla S
AD  - Pharmacology Service, Hospital Universitari de Bellvitge, L'Hospitalet de 
      Llobregat, Barcelona, Spain.
FAU - Podzamczer, Daniel
AU  - Podzamczer D
AD  - HIV and STI Unit, Infectious Disease Service, Hospital Universitari de 
      Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, 
      Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Amides)
RN  - 0 (HIV Integrase Inhibitors)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - 8GB79LOJ07 (bictegravir)
SB  - IM
MH  - Adult
MH  - Amides
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - HIV Integrase Inhibitors/cerebrospinal fluid/*pharmacokinetics/therapeutic use
MH  - HIV-1/drug effects/physiology
MH  - Heterocyclic Compounds, 3-Ring
MH  - Heterocyclic Compounds, 4 or More Rings/cerebrospinal 
      fluid/*pharmacokinetics/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Piperazines
MH  - Pyridones
MH  - Virus Replication/drug effects
MH  - Young Adult
OTO - NOTNLM
OT  - CNS
OT  - bictegravir
OT  - concentrations
OT  - unbound
EDAT- 2019/12/01 06:00
MHDA- 2021/02/05 06:00
CRDT- 2019/12/01 06:00
PHST- 2019/08/13 00:00 [received]
PHST- 2019/11/21 00:00 [accepted]
PHST- 2019/12/01 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2019/12/01 06:00 [entrez]
AID - 5648079 [pii]
AID - 10.1093/infdis/jiz624 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Apr 7;221(9):1425-1428. doi: 10.1093/infdis/jiz624.